Compare BIO-TECHNE Corp (TECH) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Target Corporation — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.37B), while Target Corporation trades at $154.8 (market cap $68.56B). The key difference: Target Corporation is far larger — about 6× BIO-TECHNE Corp's market cap, and Target Corporation pays the higher dividend (3.07%). Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Target Corporation for 137 Days on average.
| TECH | TGT | |
|---|---|---|
Market Cap | $11.37B | $68.56B |
Volume | 3,153,511 | 4,507,338 |
Sector | Health | Consumer Staples |
52-Week High | $72.61 | $169.90 |
52-Week Low | $43.31 | $83.68 |
Typical Hold Time | 63 Days | 137 Days |
Enterprise Value | $11.40B | $81.84B |
Dividend Yield | 0.44% | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Target Corporation (TGT) trades at $154.76, up 0.28% with strong technical support at $150. The stock shows solid fundamentals with a P/E of 15.66 and consistent earnings beats in recent quarters. Analyst consensus is mixed with 46.7% buy ratings and a $167.18 price target. Recent news highlights Target's holiday price-cutting strategy to capture market share amid competitive retail pressures.
Target presents a balanced opportunity with attractive valuation metrics and dividend stability, though facing margin pressure from aggressive pricing strategies. Key risks include retail competition and consumer spending sensitivity. Upside potential exists if holiday sales outperform expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
